Forest Laboratories, Inc. - Product Pipeline Review - 2014

Date: July 31, 2014
Pages: 75
Price:
US$ 1,500.00 US$ 1,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FB14DC71C22EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Forest Laboratories, Inc. - Product Pipeline Review - 2014’, provides an overview of the Forest Laboratories, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Forest Laboratories, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Forest Laboratories, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Forest Laboratories, Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Forest Laboratories, Inc.’s pipeline products
Reasons to buy
  • Evaluate Forest Laboratories, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Forest Laboratories, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Forest Laboratories, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Forest Laboratories, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Forest Laboratories, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Explore the dormant and discontinued projects of Forest Laboratories, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Forest Laboratories, Inc. Snapshot
Forest Laboratories, Inc. Overview
Key Information
Key Facts
Forest Laboratories, Inc. - Research and Development Overview
Key Therapeutic Areas
Forest Laboratories, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Forest Laboratories, Inc. - Pipeline Products Glance
Forest Laboratories, Inc. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Forest Laboratories, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Forest Laboratories, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Forest Laboratories, Inc. - Drug Profiles
(memantine hydrochloride ER + donepezil hydrochloride)
Product Description
Mechanism of Action
R&D Progress
(nebivolol + valsartan)
Product Description
Mechanism of Action
R&D Progress
levofloxacin
Product Description
Mechanism of Action
R&D Progress
cariprazine
Product Description
Mechanism of Action
R&D Progress
(aclidinium bromide + formoterol fumarate)
Product Description
Mechanism of Action
R&D Progress
(ceftazidime + avibactam)
Product Description
Mechanism of Action
R&D Progress
pancrelipase DR
Product Description
Mechanism of Action
R&D Progress
(ceftaroline + avibactam)
Product Description
Mechanism of Action
R&D Progress
cebranopadol
Product Description
Mechanism of Action
R&D Progress
memantine hydrochloride
Product Description
Mechanism of Action
R&D Progress
EUR-1100
Product Description
Mechanism of Action
R&D Progress
linaclotide
Product Description
Mechanism of Action
R&D Progress
ATL-1222
Product Description
Mechanism of Action
R&D Progress
Forest Laboratories, Inc. - Pipeline Analysis
Forest Laboratories, Inc. - Pipeline Products by Target
Forest Laboratories, Inc. - Pipeline Products by Route of Administration
Forest Laboratories, Inc. - Pipeline Products by Molecule Type
Forest Laboratories, Inc. - Pipeline Products by Mechanism of Action
Forest Laboratories, Inc. - Recent Pipeline Updates
Forest Laboratories, Inc. - Dormant Projects
Forest Laboratories, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
alvameline maleate
dexloxiglumide
ME-1036
oglemilast
radiprodil
Forest Laboratories, Inc. - Company Statement
Forest Laboratories, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Forest Laboratories, Inc., Key Information
Forest Laboratories, Inc., Key Facts
Forest Laboratories, Inc. - Pipeline by Indication, 2014
Forest Laboratories, Inc. - Pipeline by Stage of Development, 2014
Forest Laboratories, Inc. - Monotherapy Products in Pipeline, 2014
Forest Laboratories, Inc. - Combination Treatment Modalities in Pipeline, 2014
Forest Laboratories, Inc. - Partnered Products in Pipeline, 2014
Forest Laboratories, Inc. - Partnered Products/ Combination Treatment Modalities, 2014
Forest Laboratories, Inc. - Pre-Registration, 2014
Forest Laboratories, Inc. - Filing rejected/Withdrawn, 2014
Forest Laboratories, Inc. - Phase III, 2014
Forest Laboratories, Inc. - Phase II, 2014
Forest Laboratories, Inc. - Phase I, 2014
Forest Laboratories, Inc. - Preclinical, 2014
Forest Laboratories, Inc. - Pipeline by Target, 2014
Forest Laboratories, Inc. - Pipeline by Route of Administration, 2014
Forest Laboratories, Inc. - Pipeline by Molecule Type, 2014
Forest Laboratories, Inc. - Pipeline Products by Mechanism of Action, 2014
Forest Laboratories, Inc. - Recent Pipeline Updates, 2014
Forest Laboratories, Inc. - Dormant Developmental Projects,2014
Forest Laboratories, Inc. - Discontinued Pipeline Products, 2014
Forest Laboratories, Inc., Other Locations
Forest Laboratories, Inc., Subsidiaries

LIST OF FIGURES

Forest Laboratories, Inc. - Pipeline by Top 10 Indication, 2014
Forest Laboratories, Inc. - Pipeline by Stage of Development, 2014
Forest Laboratories, Inc. - Monotherapy Products in Pipeline, 2014
Forest Laboratories, Inc. - Combination Treatment Modalities in Pipeline, 2014
Forest Laboratories, Inc. - Partnered Products in Pipeline, 2014
Forest Laboratories, Inc. - Pipeline by Top 10 Target, 2014
Forest Laboratories, Inc. - Pipeline by Top 10 Route of Administration, 2014
Forest Laboratories, Inc. - Pipeline by Top 10 Molecule Type, 2014
Forest Laboratories, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Skip to top


Ask Your Question

Forest Laboratories, Inc. - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: